HIV-1 DNA耐药基因分型的样本内变异性评估
该研究评估同一次采血样本内HIV-1 DNA基因型耐药检测的变异性。12例接受抗逆转录病毒治疗患者的单次采血样本分成5份1 mL等分样本,用实时PCR定量HIV-1 DNA,并用Sentosa平台NGS进行基因型检测。结果显示样本内HIV-1 DNA定量存在显著变异,部分患者等分样本间耐药相关突变谱不一致,重复检测有时可提供额外信息,但临床影响待进一步研究。
要点
- 同一样本不同等分间HIV-1 DNA定量变异系数可达23%至89%。
- 20%阈值下,部分患者等分样本间逆转录酶、蛋白酶和整合酶基因RAM谱不一致。
- 10%阈值可检出额外突变,但未改善样本内一致性。
核心结论
- HIV-1 DNA耐药检测结果存在样本内变异性,重复检测有时可提供额外信息,但其临床影响仍需进一步研究。
研究设计与样本
- 对每例纳入患者的单次静脉采血样本分成5份1 mL等分样本,在同一批次中独立检测。
- 共检测来自12例患者的12份样本的60份等分样本,患者中位年龄45.50岁,均接受抗逆转录病毒治疗。
- HIV-1 DNA用实时PCR定量,NGS采用Sentosa平台联合Sentosa SQ HIV基因分型试剂盒。
主要发现
- 同一样本不同等分间HIV-1 DNA定量有时可见显著变异,变异系数范围为23%至89%。
- 以20%为阈值分析耐药相关突变(RAMs),分别有5例、3例和3例患者在同一样本的等分样本间出现逆转录酶、蛋白酶和整合酶基因RAM谱不一致。
- 以10%为阈值分析可检出额外突变,但未改善样本内一致性。
关键数值与推荐
- RAMs分析采用20%阈值,另以10%阈值分析。
- HIV-1 DNA定量变异系数范围为23%至89%。
临床怎么用
- 临床解读HIV-1 DNA耐药基因分型结果时需注意样本内变异可能,尤其当RAM接近检测阈值时。
- 对结果不确定或关键突变存疑时,可考虑重复检测以获取额外信息。
局限性
- 样本量较小,仅12例患者。
- 样本内变异性的临床影响尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: HIV-1 drug resistance testing can be performed in proviral DNA. The non-homogenous distribution of viral variants in cells can impact the performance of this method. We assessed the variability of HIV-1 DNA genotyping results in the same blood sample using a next-generation sequencing (NGS) method. METHODS: For each included patient, a blood sample from a single venipuncture was split into five 1 mL aliquots, which were independently tested in the same run. HIV-1 DNA was quantified in blood samples using real-time PCR, and NGS was performed with the Sentosa platform combined with the Sentosa SQ HIV genotyping Assay. RESULTS: A total of 60 aliquots from 12 samples (12 patients) were tested. The median age was 45.50 years old, and all patients were treated with antiretrovirals. A significant variability can sometimes be observed in HIV-1 DNA quantification between aliquots from the same sample, with a coefficient of variation ranging from 23% to 89%. The analysis of resistance-associated mutations (RAMs) with a 20% cut-off found some discordances in RAMs profile between aliquots from the same sample for 5, 3 and 3 patients in the reverse transcriptase, protease and integrase genes, respectively. The analysis with a lower cut-off (10%) showed additional mutations, but did not improve the intra-sample concordance. CONCLUSIONS: There is an intra-sample variability in HIV-1 DNA resistance test results, and repetition may sometimes bring additional information, but the extent of its clinical impact still requires further investigation.
引用
- Millière L, Bocket L, Tinez C, et al. Assessment of intra-sample variability in HIV-1 DNA drug resistance genotyping. J Antimicrob Chemother. 2021. PMID: 34050668. doi:10.1093/jac/dkab149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。